Our cohort included 23 metastatic prostate cancer samples with germline and/or somatic BRCA2d, 10 with CDK12d, 16 with MMRd, and 6 with ATM defects (ATMd) (Fig. 1b; Supplementary Data 1). The gene discussed is ATM; the disease is metastatic prostate carcinoma.